- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00531947
Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression
A Phase IV, Double-Blind, Placebo-Controlled, Randomized, Flexible Dose Study of the Safety and Efficacy of EMSAM in Adolescents With Major Depression
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Alabama
-
Dothan, Alabama, United States
- Dr. Nelson Handal
-
-
California
-
National City, California, United States
- Dr. Mohammed Bari
-
SanDiego, California, United States
- Dr. Michael McManus
-
-
Florida
-
Gainesville, Florida, United States
- Dr. Elias Sarkis
-
North Miami, Florida, United States
- Dr. Scott Segal
-
Tampa, Florida, United States
- Dr. Mary Stedman
-
Winter Park, Florida, United States
- Dr. Irving Kolin
-
-
Kansas
-
Overland Park, Kansas, United States
- Dr. Rory Murphy
-
-
Kentucky
-
Owensboro, Kentucky, United States
- Dr. Andrew Sediloo
-
-
Massachusetts
-
Springfield, Massachusetts, United States
- Dr. Bruce Waslick
-
-
Nebraska
-
Omaha, Nebraska, United States
- Dr. Christopher Kratochvil
-
-
Nevada
-
Las Vegas, Nevada, United States
- Dr. Ann Childress
-
-
Ohio
-
Cincinnati, Ohio, United States
- Dr. Melissa DelBello
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States
- Dr. Leland Dennis
-
-
Texas
-
Austin, Texas, United States
- Dr. David Brown
-
Bellaire, Texas, United States
- Dr. Alain Katic
-
Dallas, Texas, United States
- Dr. Graham Emslie
-
-
Virginia
-
Charlottesville, Virginia, United States
- Dr. Mary Shemo
-
Richmond, Virginia, United States
- Dr. John Gilliam
-
-
Washington
-
Bellevue, Washington, United States
- Dr. Arifulla Khan
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male / Female outpatients 12 to 17 years of age diagnosed with Major Depressive Disorder (MDD). (Must have a Children's Depression Rating Scale-Revised [CDRS-R] with a total score of at least 45 at screening.)
- Female patients must test negative on a pregnancy at visit 1.
- Weight and height must be greater than the 10th percentile according to age and height,
- Assent and consent must be given.
Exclusion Criteria:
- Have a serious or unstable medical illness, psychological condition, clinically significant laboratory or ECG result, hypersensitivity to selegiline, or any other condition that in the opinion of the investigator would compromise participation in the study or be likely to lead to hospitalization during the course of the study.
- Have a current or previous diagnosis of bipolar disorder, psychotic depression, schizophrenia or other psychotic disorder, anorexia, bulimia, obsessive compulsive disorder, pervasive development disorder or borderline personality disorder, as determined by the investigator.
- Have a risk of suicide
- Female patients who are either pregnant, nursing or have recently given birth.
- Use of any protocol prohibited medications or substances.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: EMSAM
Approved Medication for Major Depressive Disorder: EMSAM (Selegiline Transdermal System) 6mg, 9mg, or 12mg
|
EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study
Other Names:
|
Placebo Comparator: Placebo
Placebo Selegiline Transdermal System 6, 9 or 12
|
Matching Placebo for EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CDRS-R Total Score (Child) (mITT w/LOCF Population) Week 12
Time Frame: baseline and 12 Weeks
|
A summary of the primary efficacy outcome measure, Children's Depression Rating Scale (CDRS-R) Total Score, as reported by the Child, at Week 12 (EOS), by treatment assigned, is shown for the modified intent-to-treat (mITT) population, with the last observation carried forward (LOCF) in time. CDRS-R total raw scores range from 17(minimum) 113(maximum). A lower score indicates a lower likelihood of a depressive disorder, a higher score indicates a higher likelihood of a depressive disorder. Two subscales are summed to calculate a total score: Evaluated Symptom Area and Ratings of Observed Nonverbal Behavior. |
baseline and 12 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CGI-S - Week 12 (mITT w/LOCF Population)
Time Frame: Baseline and 12 Weeks
|
A summary of the Clinical Global Impression of Severity (CGI-S) at baseline and Week 12 (EOS), by treatment assigned, is shown for the mITT population with LOCF.
The CGI-s is the clinician's assessment of severity of illness (depression).
Scores range from 1(minimum) to 7(maximum).
A lower score indicates lower illness severity, a higher score indicates higher levels of illness severity.
|
Baseline and 12 Weeks
|
CGI-C - Week 12 (mITT w/LOCF Population)
Time Frame: 12 Weeks
|
A summary of the Clinicians Global Impression of Change (CGI-C) Score at Week 12 (EOS), by treatment assigned, is shown for the mITT population with LOCF.
The CGI-c assesses the overall change in the severity of illness (depression).
The clinician rates the subject's change based on a bipolar scale from 1(minimum; "Very much improved") to 7(maximum; "Very much worse").
A lower score indicates lower levels of depression as compared to baseline, a higher score indicates higher levels of depression as compared to baseline.
A score of 4 ("Unchanged") indicates no change in illness compared to baseline.
The scale is not calculated as a statistical change score; the clinician rates their impression of change overall.
|
12 Weeks
|
CGI-C Percent Responders (mITT w/LOCF Population)
Time Frame: 12 Weeks
|
A summary of the CGI-C percent responders at Week 12 (EOS), by treatment assigned, is shown for the mITT population with LOCF.
CGI-C responders were defined as a score of 1 or 2 at the end of the study.
A non-responder was defined as a score of ≥3 at end of study.
Maximum score is 100%.
|
12 Weeks
|
CDRS-R Total Score (Parent/Other) Week 12 (mITT w/LOCF Population)
Time Frame: Baseline and 12 Weeks
|
A summary of a secondary efficacy outcome measure, Children's Depression Rating Scale (CDRS-R) Total Score (Scored by Parent/Other), at Week 12 (EOS), by treatment assigned, is shown for the modified intent-to-treat (mITT) population, with the last observation carried forward (LOCF) in time. CDRS-R (Parent/Other) total raw scores range from 14 (minimum) 94 (maximum). A lower score indicates a lower likelihood of a depressive disorder, a higher score indicates a higher likelihood of a depressive disorder. One subscale is summed to calculate a total score: Evaluated Symptom Area. Ratings of Observed Nonverbal Behavior subscale is not included in Parent/Other total calculation. |
Baseline and 12 Weeks
|
CDRS-R Total Score (Best Description) Week 12 (mITT w/LOCF Population)
Time Frame: 12 Weeks
|
A summary of a secondary efficacy outcome measure, Children's Depression Rating Scale (CDRS-R) Total Score (Best Description), at Week 12 (EOS), by treatment assigned, is shown for the modified intent-to-treat (mITT) population, with the last observation carried forward (LOCF) in time. Best Description ratings are used when ratings based on interviews with different sources (e.g., child, parent, other ratings) differ for a particular symptom. The evaluator must determine which of these ratings most accurately represents the current affective functioning of the child, and circle that rating in the Best Description of Child Column. CDRS-R (Best Description)total raw scores range from 17(minimum) 113(maximum). A lower score indicates a lower likelihood of a depressive disorder, a higher score indicates a higher likelihood of a depressive disorder. Two subscales are summed to calculate a total score: Evaluated Symptom Area and Ratings of Observed Nonverbal Behavior. |
12 Weeks
|
CDRS-R Total Score (Child) Week 12 (mITT w/OC Population)
Time Frame: 12 Weeks
|
A summary of the secondary efficacy outcome measure, Children's Depression Rating Scale (CDRS-R) Total Score (Scored by Child), at Week 12 (EOS), by treatment assigned, is shown for the modified intent-to-treat (mITT) population with observed cases (w/OC). CDRS-R (Child) total raw scores range from 17(minimum) 113(maximum). A lower score indicates a lower likelihood of a depressive disorder, a higher score indicates a higher likelihood of a depressive disorder. Two subscales are summed to calculate a total score: Evaluated Symptom Area and Ratings of Observed Nonverbal Behavior. |
12 Weeks
|
CDRS-R Total Score (Parent/Other) Week 12 (mITT w/OC Population)
Time Frame: 12 Weeks
|
A summary of a secondary efficacy outcome measure, Children's Depression Rating Scale (CDRS-R) Total Score (Scored by Parent/Other), at Week 12 (EOS), by treatment assigned, is shown for the modified intent-to-treat (mITT) population with observed cases (w/OC). CDRS-R (Parent/Other) total raw scores range from 14 (minimum) 94 (maximum). A lower score indicates a lower likelihood of a depressive disorder, a higher score indicates a higher likelihood of a depressive disorder. One subscale is summed to calculate a total score: Evaluated Symptom Area. Ratings of Observed Nonverbal Behavior subscale is not included in Parent/Other total calculation. |
12 Weeks
|
CDRS-R Total Score (Best Description) Week 12 (mITT w/OC Population)
Time Frame: 12 Weeks
|
A summary of a secondary efficacy outcome measure, Children's Depression Rating Scale (CDRS-R) Total Score (Best Description), at Week 12 (EOS), by treatment assigned, is shown for the modified intent-to-treat (mITT) population, with observed cases (w/OC). Best Description ratings are used when ratings based on interviews with different sources (e.g., child, parent, other ratings) differ for a particular symptom area. The evaluator must determine which of these ratings most accurately represents the current affective functioning of the child, and circle that rating in the Best Description of Child Column. CDRS-R (Best Description) total raw scores range from 17(minimum) 113(maximum). A lower score indicates a lower likelihood of a depressive disorder, a higher score indicates a higher likelihood of a depressive disorder. Two subscales are summed to calculate a total score: Evaluated Symptom Area and Ratings of Observed Nonverbal Behavior. |
12 Weeks
|
Physical Examination (Screening vs. EOS)
Time Frame: 12 Weeks
|
Number of physical examination findings that were normal at screening, but abnormal at end of study are presented.
Four subjects receiving placebo and four subjects receiving EMSAM had abnormal findings on physical examination at the end of study that were normal at screening.
|
12 Weeks
|
Urinalysis (Change From Baseline)
Time Frame: 12 Weeks
|
A summary of a secondary safety outcome measure, Urinalysis (Change from Baseline), by treatment assigned, is shown for the safety population.
Mean changes from baseline are provided for PH and specific gravity.
|
12 Weeks
|
Vital Signs-Heart Rate (Change From Baseline)
Time Frame: 12 Weeks
|
Summary mean change in heart rate measured in beats per minute (beats/min or BPM) (supine, standing, and orthostatic change)results for all subjects are presented.
|
12 Weeks
|
Vital Signs-Blood Pressure (Change From Baseline)
Time Frame: 12 Weeks
|
Summary mean change in blood pressure (systolic/diastolic) measured in millimeters of mercury (mmHg) (supine, standing, and orthostatic change)results for all subjects are presented.
|
12 Weeks
|
12 Lead ECG (Change From Baseline)
Time Frame: 12 Weeks
|
A summary of a secondary safety outcome measure, 12 Lead electrocardiogram (ECG) (Change from Baseline) measured in milliseconds (msec), by treatment assigned, is shown for the safety population.
Mean change from Baseline in PR interval, QRS duration, QT interval, and QTc (Bazett and Fridericia corrections) interval are presented.
|
12 Weeks
|
12 Lead ECG (Change From Baseline)Ventricular Heart Rate
Time Frame: 12 Weeks
|
A summary of a secondary safety outcome measure, 12 Lead electrocardiogram (ECG) (Change from Baseline)Ventricular Heart Rate measured in beats per minute(beats/min or BPM), by treatment assigned, is shown for the safety population.
Mean change from baseline is presented.
|
12 Weeks
|
Hematology - White Blood Cell (WBC) (Change From Baseline)
Time Frame: 12 Weeks
|
A summary of a secondary safety outcome measure, Hematology (Change from Baseline), by treatment assigned, is shown for the safety population.
Mean change from Baseline in ABS BASOPHILS (X10^9/L), ABS EOSINOPHILS (X10^9/L), ABS LYMPHOCYTES (X10^9/L), ABS MONOCYTES (X10^9/L), and ABS NEUTROPHILS (X10^9/L) are presented.
|
12 Weeks
|
Hematology - Hematocrit (Change From Baseline)
Time Frame: 12 Weeks
|
A summary of a secondary safety outcome measure, Hematology - Hematocrit(HCT)(Change from Baseline), by treatment assigned, is shown for the safety population.
|
12 Weeks
|
Hematology - Hemoglobin (Change From Baseline)
Time Frame: 12 Weeks
|
A summary of a secondary safety outcome measure, Hematology - Hemoglobin(HGB)(Change from Baseline), by treatment assigned, is shown for the safety population.
|
12 Weeks
|
Hematology - Red Blood Cell (Change From Baseline)
Time Frame: 12 Weeks
|
A summary of a secondary safety outcome measure, Hematology - Red Blood Cell (RBC)(Change from Baseline), by treatment assigned, is shown for the safety population.
|
12 Weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Thomas Hochadel, Pharm.D., Cognitive Research Corporation
- Study Chair: Melissa L Goodhead, Somerset Pharmaceuticals
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Mood Disorders
- Depression
- Depressive Disorder
- Depressive Disorder, Major
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Neuroprotective Agents
- Protective Agents
- Psychotropic Drugs
- Antidepressive Agents
- Monoamine Oxidase Inhibitors
- Antiparkinson Agents
- Anti-Dyskinesia Agents
- Selegiline
Other Study ID Numbers
- S9303-P0605
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depressive Disorder
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
AccexibleRecruitingMajor Depressive Disorder (MDD)Spain
Clinical Trials on Selegiline Transdermal System
-
Somerset PharmaceuticalsCompleted
-
Somerset PharmaceuticalsCompleted
-
Somerset PharmaceuticalsCompletedMajor DepressionUnited States
-
New York State Psychiatric InstituteTerminated
-
National Institute on Drug Abuse (NIDA)VA Office of Research and DevelopmentCompleted
-
National Institute on Drug Abuse (NIDA)CompletedMarijuana AbuseUnited States
-
Northwestern University3MCompletedHealthyUnited States
-
Mundipharma Pte Ltd.Mundipharma Korea Ltd; Mundipharma (Hong Kong) Ltd; Mundipharma Distribution...CompletedOsteoarthritis | Rheumatoid Arthritis | Lower Back Pain | Joint Pain | Muscle PainHong Kong, Korea, Republic of, Philippines
-
National Institute of Allergy and Infectious Diseases...National Institute of Neurological Disorders and Stroke (NINDS); Neurologic...CompletedHIV Infections | Cognition DisordersUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedHIV Infections | Cognitive DisordersUnited States